ReviewCurrent opinion in pharmacology2008
siRNA and the lung: research tool or therapeutic drug?
Review in Current opinion in pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Pulmonary siRNA Delivery with Sophisticated Amphiphilic Poly(Spermine Acrylamides) for the Treatment of Lung Fibrosis.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application.Pharmaceutics · 2022Review
- Extension in the approaches to treat cancer through siRNA system: a beacon of hope in cancer therapy.Drug delivery and translational research · 2022Review
- Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases.Chemico-biological interactions · 2019Review
- Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery Systems.Kona : powder science and technology in Japan · 2017Article
- Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems.Kona : powder science and technology in Japan · 2016Article
- siRNA delivery to the lung: what's new?Advanced drug delivery reviews · 2014Review
- Antisense therapeutics in oncology: current status.OncoTargets and therapy · 2014Review
- Article
- Polymers in small-interfering RNA delivery.Nucleic acid therapeutics · 2011Review
- Local pulmonary immunotherapy with siRNA targeting TGFβ1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice.Tuberculosis (Edinburgh, Scotland) · 2011Article
- Pulmonary gene silencing in transgenic EGFP mice using aerosolised chitosan/siRNA nanoparticles.Pharmaceutical research · 2010Article
- Knocking down barriers: advances in siRNA delivery.Nature reviews. Drug discovery · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oligonucleotide-based therapeutics have been hailed as 'the next great wave of the biotechnology revolution' starting with antisense oligonucleotides (ASOs) nearly 20 years ago to RNA interference (RNAi) currently. Is RNAi just the latest research tool or does it have real potential as a therapeutic drug modality? As a research tool, it is evident that RNAi has revolutionized the biological sciences by allowing selective silencing of messenger RNA (mRNA) expression. With the advent of the postgenomic era, RNAi offers a therapeutic platform on which to identify potential picomolar active drug candidates to any target, including those that are conventionally undruggable. In this review, we will discuss the progress made in developing RNAi therapeutics for the treatment of respiratory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.